Fosun Pharma withdraws plans to sell stake in Gland Pharma

Bengaluru: China's Shanghai Fosun Pharmaceutical Group Co Ltd has withdrawn plans to sell stake in Indian drugmaker Gland Pharma Ltd, ET Now tweeted on Wednesday, citing sources.

Fosun Pharma holds a 57.86% stake in the Indian company. Both Fosun Pharma and Gland Pharma did not immediately respond to Reuters' requests for comment.

Read also: Fosun Pharma said to mull sale of USD 3.6 billion Gland Pharma

Shares of Gland Pharma were up 0.8% at 1,360 rupees as of 9:50 a.m. IST. They have plunged 28% since November end, when Bloomberg News had reported, citing sources that Fosun Pharma was considering a sale of Gland Pharma after receiving interest from potential buyers.

Read also: Gland Pharma to infuse Rs 400 crore to expand Genome Valley facility









from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/2NIVrfK

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

ICMR invites proposals for Centre for Advanced Research under Extramural Research Program, Details

Image
New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program. The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.   What the CAR is expected to do: Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention. Priority diseases or conditions: Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilita...
Read more

Zasocitinib therapy highly efficacious for treatment of severe plaque psoriasis: JAMA

Image
A recent study published in the Journal of American Medical Association revealed that Zasocitinib could be a breakthrough in the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin condition characterized by red, scaly patches, affects millions throughout the globe. While several treatments exist, the demand for new, effective, and well-tolerated oral therapies remains high. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, emerges as a promising candidate to meet this need. This trial was conducted between August 2021 and September 2022 across 55 centers in the US and Canada and found that Zasocitinib not only significantly improved skin clearance in patients but also expressed a favorable safety and tolerability profile. The study enrolled a total of 287 participants aged between 18 and 70 years, each with a Psoriasis Area and Severity Index (PASI) score of 12 or greater, a Physician’s Global Assessment score of 3...
Read more